Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein

• Nanobody is applied in detecting AFP in stead of traditional IgG antibody.
• IPCR technology based on nanobody couple with high sesitivity, broad linear range.
• The principles of AFP assays are applicable to detection other cancer biomarker.

Immunoassay for cancer biomarkers plays an important role in cancer prevention and early diagnosis. To the development of immunoassay, the quality and stability of applied antibody is one of the key points to obtain reliability and high sensitivity for immunoassay. The main purpose of this study was to develop a novel immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein (AFP) based on nanobody against AFP. Two nanobodies which bind to AFP were selected from a phage display nanobody library by biopanning strategy. The prepared nanobodies are clonable, thermally stable and applied in both sandwich enzyme linked immunoassay (ELISA) and immuno-PCR assay for ultrasensitive detection of AFP. The limit detection of sandwich ELISA setup with optimized nanobodies was 0.48 ng mL−1, and the half of saturation concentration (SC50) value was 6.68±0.56 ng mL−1. These nanobodies were also used to develop an immuno-PCR assay for ultrasensitive detection of AFP, its limit detection values was 0.005 ng mL−1, and the linear range was 0.01–10,000 ng mL−1. These established immunoassays based on nanobodies were highly specific to AFP and with negligible cross reactivity with other tested caner biomarkers. Furthermore, this novel concept of nanobodies mediated immunoassay may provide potential applications in a general method for the ultrasensitive detection of various cancer biomarkers.

Figure optionsDownload as PowerPoint slide